PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20843517-4	2010	Pactimibe, a nonselective inhibitor of ACAT-1 and ACAT-2, reduced plasma cholesterol levels but did not affect macrophage- or collagen-positive areas.	pactimibe	0-9	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	39-45
20843517-4	2010	Pactimibe, a nonselective inhibitor of ACAT-1 and ACAT-2, reduced plasma cholesterol levels but did not affect macrophage- or collagen-positive areas.	pactimibe	0-9	acetyl-Coenzyme A acetyltransferase 2	Mus musculus	50-56
18448569-1	2008	Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor developed for the treatment of hypercholesterolemia and atherosclerotic diseases.	pactimibe	0-17	carboxylesterase 1	Homo sapiens	29-72
18448569-2	2008	Pactimibe has two equally dominant clearance pathways forming R-125528 by CYP3A4 and M-1 by CYP2D6 in vitro.	pactimibe	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
18448569-2	2008	Pactimibe has two equally dominant clearance pathways forming R-125528 by CYP3A4 and M-1 by CYP2D6 in vitro.	pactimibe	0-9	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
19293413-1	2009	CONTEXT: Inhibition of acyl coenzyme A:cholesterol acyltransferase (ACAT), an intracellular enzyme involved in cholesterol accumulation, with pactimibe was developed to assist in the prevention of cardiovascular disease.	pactimibe	142-151	carboxylesterase 1	Homo sapiens	23-66
19293413-1	2009	CONTEXT: Inhibition of acyl coenzyme A:cholesterol acyltransferase (ACAT), an intracellular enzyme involved in cholesterol accumulation, with pactimibe was developed to assist in the prevention of cardiovascular disease.	pactimibe	142-151	carboxylesterase 1	Homo sapiens	68-72
19000552-2	2008	The pharmacokinetics of pactimibe and its pharmacologically inactive plasma metabolite, R-125528, of which the main clearance pathway is CYP2D6, was affected by coadministration of quinidine.	pactimibe	24-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143
19000552-3	2008	The aim of this study was to investigate the influence of CYP2D6 polymorphism on pharmacokinetics of pactimibe and R-125528.	pactimibe	101-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
19000552-4	2008	In addition, exposure was examined after multiple doses of pactimibe sulfate in CYP2D6 poor metabolizer (PMs).	pactimibe	59-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
19000552-8	2008	After multiple doses of 100 mg pactimibe to CYP2D6 PMs, the accumulation ratio of R-125528 reached 8.8-fold, however, the exposure of R-125528 in CYP2D6 PMs was covered by the exposure in additional metabolite safety testing.	pactimibe	31-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
19000552-8	2008	After multiple doses of 100 mg pactimibe to CYP2D6 PMs, the accumulation ratio of R-125528 reached 8.8-fold, however, the exposure of R-125528 in CYP2D6 PMs was covered by the exposure in additional metabolite safety testing.	pactimibe	31-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	146-152
19000552-9	2008	CONCLUSIONS: Although CYP2D6 polymorphism greatly affected the pharmacokinetics of R-125528 rather than pactimibe, the exposure in CYP2D6 PMs after a multiple dose of 100 mg pactimibe sulfate was covered by additional non-clinical metabolite safety testing.	pactimibe	174-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	22-28
19000552-9	2008	CONCLUSIONS: Although CYP2D6 polymorphism greatly affected the pharmacokinetics of R-125528 rather than pactimibe, the exposure in CYP2D6 PMs after a multiple dose of 100 mg pactimibe sulfate was covered by additional non-clinical metabolite safety testing.	pactimibe	174-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
18524873-9	2008	The effect of the N-alkyl chain length of pactimibe analogs on their CYP2D6 metabolic stability was plausibly explained by the docking model.	pactimibe	42-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
18056254-0	2008	CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.	pactimibe	93-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
18056254-0	2008	CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.	pactimibe	93-102	carboxylesterase 1	Homo sapiens	38-81
18056254-1	2008	Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor.	pactimibe	0-17	carboxylesterase 1	Homo sapiens	29-72
16626720-0	2007	ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.	pactimibe	15-32	sterol O-acyltransferase 2	Mus musculus	0-4
16626720-0	2007	ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.	pactimibe	15-32	apolipoprotein E	Mus musculus	135-151
16626720-0	2007	ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.	pactimibe	34-40	sterol O-acyltransferase 2	Mus musculus	0-4
16626720-0	2007	ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.	pactimibe	34-40	apolipoprotein E	Mus musculus	135-151
16626720-1	2007	The objective of the present study was to determine whether a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, pactimibe sulfate (CS-505), could reduce atherosclerotic lesions beyond and independent of the reduction achieved by cholesterol lowering alone from two different types of lesions.	pactimibe	123-140	sterol O-acyltransferase 2	Mus musculus	68-104
16626720-1	2007	The objective of the present study was to determine whether a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, pactimibe sulfate (CS-505), could reduce atherosclerotic lesions beyond and independent of the reduction achieved by cholesterol lowering alone from two different types of lesions.	pactimibe	123-140	sterol O-acyltransferase 2	Mus musculus	106-110
16626720-1	2007	The objective of the present study was to determine whether a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, pactimibe sulfate (CS-505), could reduce atherosclerotic lesions beyond and independent of the reduction achieved by cholesterol lowering alone from two different types of lesions.	pactimibe	142-148	sterol O-acyltransferase 2	Mus musculus	68-104
16626720-1	2007	The objective of the present study was to determine whether a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, pactimibe sulfate (CS-505), could reduce atherosclerotic lesions beyond and independent of the reduction achieved by cholesterol lowering alone from two different types of lesions.	pactimibe	142-148	sterol O-acyltransferase 2	Mus musculus	106-110
16730694-0	2006	Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.	pactimibe	114-123	sterol O-acyltransferase 1	Homo sapiens	14-59
16730694-1	2006	Pactimibe sulfate, [7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid hemisulfate, a novel Acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, was investigated in vitro and in vivo to characterize its potential.	pactimibe	0-17	carboxylesterase 1	Homo sapiens	114-157
16730694-1	2006	Pactimibe sulfate, [7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid hemisulfate, a novel Acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, was investigated in vitro and in vivo to characterize its potential.	pactimibe	0-17	carboxylesterase 1	Homo sapiens	159-163
16730694-2	2006	Pactimibe exhibited dual inhibition for ACAT1 and ACAT2 (concentrations inhibiting 50% [IC50s] at micromolar levels) more potently than avasimibe.	pactimibe	0-9	acetyl-CoA acetyltransferase 1	Homo sapiens	40-45
16730694-8	2006	These results suggest that ACAT1/2 dual inhibitor pactimibe has anti-atherosclerotic potential beyond its plasma cholesterol-lowering activity.	pactimibe	50-59	acetyl-CoA acetyltransferase 1	Homo sapiens	27-32
16690054-0	2006	Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.	pactimibe	0-9	sterol O-acyltransferase 1	Oryctolagus cuniculus	63-99
16690054-1	2006	Novel acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor pactimibe was administered as the sulfate salt form to 3-month-old homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits at doses of 0, 10, or 30 mg/kg for 32 weeks.	pactimibe	67-76	liver carboxylesterase 1	Oryctolagus cuniculus	6-49
16690054-1	2006	Novel acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor pactimibe was administered as the sulfate salt form to 3-month-old homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits at doses of 0, 10, or 30 mg/kg for 32 weeks.	pactimibe	67-76	sterol O-acyltransferase 1	Oryctolagus cuniculus	51-55
16554527-5	2006	Patients were randomly assigned to receive the ACAT inhibitor pactimibe (100 mg per day) or matching placebo.	pactimibe	62-71	carboxylesterase 1	Homo sapiens	47-51